184 related articles for article (PubMed ID: 37095347)
21. Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice.
Luan N; Cao H; Wang Y; Lin K; Hu J; Liu C
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376650
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines.
Han X; Alameh MG; Butowska K; Knox JJ; Lundgreen K; Ghattas M; Gong N; Xue L; Xu Y; Lavertu M; Bates P; Xu J; Nie G; Zhong Y; Weissman D; Mitchell MJ
Nat Nanotechnol; 2023 Sep; 18(9):1105-1114. PubMed ID: 37365276
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.
Wu Y; Zhang H; Meng L; Li F; Yu C
Front Immunol; 2022; 13():906457. PubMed ID: 35663946
[TBL] [Abstract][Full Text] [Related]
24. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.
Trougakos IP; Terpos E; Alexopoulos H; Politou M; Paraskevis D; Scorilas A; Kastritis E; Andreakos E; Dimopoulos MA
Trends Mol Med; 2022 Jul; 28(7):542-554. PubMed ID: 35537987
[TBL] [Abstract][Full Text] [Related]
25. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
[TBL] [Abstract][Full Text] [Related]
26. Ferritin-binding and ubiquitination-modified mRNA vaccines induce potent immune responses and protective efficacy against SARS-CoV-2.
Yu T; Zhang C; Xing J; Zhang T; Xu Z; Di Y; Yang S; Jiang R; Tang J; Zhuang X; Jin N; Tian M
Int Immunopharmacol; 2024 Mar; 129():111630. PubMed ID: 38320355
[TBL] [Abstract][Full Text] [Related]
27. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
28. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
[TBL] [Abstract][Full Text] [Related]
29. Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins.
Cacciottolo M; Nice JB; Li Y; LeClaire MJ; Twaddle R; Mora CL; Adachi SY; Chin ER; Young M; Angeles J; Elliott K; Sun M
Microbiol Spectr; 2023 Jun; 11(3):e0050323. PubMed ID: 37093009
[TBL] [Abstract][Full Text] [Related]
30. Advances in COVID-19 mRNA vaccine development.
Fang E; Liu X; Li M; Zhang Z; Song L; Zhu B; Wu X; Liu J; Zhao D; Li Y
Signal Transduct Target Ther; 2022 Mar; 7(1):94. PubMed ID: 35322018
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2.
Salleh MZ; Norazmi MN; Deris ZZ
PeerJ; 2022; 10():e13083. PubMed ID: 35287350
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
[TBL] [Abstract][Full Text] [Related]
33. Split-Dose Administration Enhances Immune Responses Elicited by a mRNA/Lipid Nanoparticle Vaccine Expressing Respiratory Syncytial Virus F Protein.
Austin LA; Smith JS; Nahas DD; Danzinger A; Secore S; O'Donnell G; Radcliffe S; Hu S; Perley J; Bett AJ; Gindy ME
Mol Pharm; 2023 Jan; 20(1):279-289. PubMed ID: 36251490
[TBL] [Abstract][Full Text] [Related]
34. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
35. A Newly Identified Spike Protein Targeted Linear B-Cell Epitope Based Dissolvable Microneedle Array Successfully Eliciting Neutralizing Activities against SARS-CoV-2 Wild-Type Strain in Mice.
Li L; Zhao Z; Yang X; Su Z; Li W; Chen S; Wang L; Sun T; Du C; Li Z; Yang Z; Li M; Wang T; Wang Y; Fan Y; Wang H; Zhang J
Adv Sci (Weinh); 2023 Jul; 10(20):e2207474. PubMed ID: 37162232
[TBL] [Abstract][Full Text] [Related]
36. Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies.
Li M; Li S; Huang Y; Chen H; Zhang S; Zhang Z; Wu W; Zeng X; Zhou B; Li B
Adv Mater; 2021 Aug; 33(34):e2101707. PubMed ID: 34278613
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 mRNA vaccines: Platforms and current developments.
Szabó GT; Mahiny AJ; Vlatkovic I
Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N
Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769
[TBL] [Abstract][Full Text] [Related]
39. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity.
Pierobon A; Zotto AD; Antico A; De Antoni ME; Vianello L; Gennari M; Di Caprio A; Russo F; Brambilla G; Saugo M
Clin Microbiol Infect; 2022 Apr; 28(4):614.e5-614.e7. PubMed ID: 34958917
[TBL] [Abstract][Full Text] [Related]
40. Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19.
Yin Y; Su W; Zhang J; Huang W; Li X; Ma H; Tan M; Song H; Cao G; Yu S; Yu D; Jeong JH; Zhao X; Li H; Nie G; Wang H
ACS Nano; 2021 Sep; 15(9):14347-14359. PubMed ID: 34472328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
